From the Editor's Desk
© 2005 Prime Health Consultants, Inc.
In this issue the international contributing editors of GGH began abstracting papers for the readership. They reviewed the literature, selected important publications, abstracted them, and made insightful and important comments. Thus, with these contributions we continue to expand the reach of the journal. On behalf of everyone I thank them for their contributions and welcome them.
The lead article covers an important area that clinicians often encounter, namely evaluating the growth of patients with neurofibromatosis type 1. Growth alterations affect 13% to 24% of children with this disease, with more than 40% of adult NF1 patients reaching a decreased final height. Drs. Karantza and Geffner have written a notable review outlining the most pertinent issues of growth and growth hormone in NF1 patients. I am sure that this lead article will be tremendously useful and will constitute an important reference.
Additionally, the highlights of the 87th annual meeting of the Endocrine Society are summarized and 8 abstracts are presented in this printed GGH. There are 7 more abstracts posted on the web at www.GGHjournal.com. I trust you will enjoy and treasure this issue.
The next issue will include a historical review of growth hormone that commemorates the 20th anniversary of the FDA approval of recombinant human growth hormone and the launching of GGH - both made possible by Genentech.
Fima Lifshitz, MD